Ziprasidone hydrochloride - CP 88059

Based on 12 reference(s) in Google Scholar 9 10 12

Axon 1446

CAS [122883-93-6]

MF C21H21ClN4OS.HCl
MW 449.40

Purity: 99%
Soluble in DMSO

Ziprasidone hydrochloride

Description

A 5-HT2A/5-HT2C and dopamine D2 antagonist, 5-HT1A agonist; an atypical antipsychotic for the treatment of schizophrenia and acute bipolar disorder including manic and mixed episodes; Oral bioavailability 59%; Antipsychotic effects at oral doses of 20 mg.

DC Goff et al. An exploratory haloperidol-controlled dose-finding study of ziprasidone in hospitalized patients with schizophrenia or schizoaffective disorder. J. Clin. Psychopharmacol 1998, 18(4), 296-304.

CB Nemeroff et al. From clinical research to clinical practice: a 4-year review of ziprasidone. CNS Spectr 2005, 10 (11 Suppl 17), 1–20.

TF Seeger et al. Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity. J. Pharmacol. Exp. Ther. 2005, 275(1), 101–13.

CNS D2 5-HT1A 5-HT2A 5-HT2C A17 Pfizer Licensed Products

Atypical antipsychotic

Chemical name

5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2H-Indol-2-one hydrochloride

Source information

Pfizer compound; Sold for research purposes under agreement from Pfizer Inc.

Parent CAS No.

[146939-27-7]

产品资料